Apeiron Investment, a family office and merchant banking business of Christian Angermayer, led a $157m Series D round in atai Life Sciences, a clinical-stage biopharmaceutical company, with participation from Thiel Capital and Woodline Partners. "This marks a monumental moment for atai; we continue on our mission challenging the current way mental health conditions are treated. We have become better equipped than ever to accelerate the development of more efficacious treatments. With support from our investors, we are determined to improve care and innovate," Florian Brand, atai CEO & Co-Founder.